Stat5 as a diagnostic marker for leukemia

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 73-82

  Lewis, Rowena S ^b   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cytokine signaling; Diagnostics; Hematology; Jak Stat pathway; Leukemia; Myeloproliferation; Oncology; Stat5; Therapeutics

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CURCUMIN; DASATINIB; GTP 14564; IMATINIB; MIDOSTAURIN; PROTEIN INHIBITOR; SEMAXANIB; SORAFENIB; STAT5 PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

CHRONIC MYELOID LEUKEMIA; DISEASE MARKER; DRUG MECHANISM; DRUG TARGETING; LEUKEMIA; MYELOPROLIFERATIVE DISORDER; ONCOGENE; PROTEIN FUNCTION; REVIEW; T CELL LEUKEMIA; HUMAN; METABOLISM;

HUMANS; LEUKEMIA; STAT5 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 38149109907     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.73     Document Type: Review

References (144)

1. Bromberg JF. Activation of Stat proteins and growth control. BioEssays 23, 161-169 (2001). • Concise overview of the role of Stats in proliferation and growth control.
2. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathway and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164), 1415-1421 (1994).
3. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95(1), 19-29 (2000).
4. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol. Immunol. 44(10), 2497-2506 (2007). • Recent comprehensive review of the role of the Jak-Stat-Socs pathway in cytokine signaling and disease
5. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19(5), 378-387 (2001).
6. Hanada T, Kinjyo I, Inagaki-Ohara K, Yoshimura A. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev. Physiol. Biochem. Pharmacol. 149, 72-86 (2003).
7. Zhang JG, Farley A, Nicholson SE et al. The conserved Socs box motif in suppressors of cytokine signalling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl Acad. Sci. USA 96, 2071-2076 (1999).
8. Copeland NG, Gilbert DJ, Schindler C et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29, 225-228 (1995).
9. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 13(18), 4361-4369 (1994).
10. Miyakawa Y, Oda A, Druker BJ et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 87, 439-446 (1996).
11. Pallard C, Gouilleux F, Benit L et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 14, 2847-2856 (1995).
12. Iwatsuki K, Endo T, Misawa H et al. Stat5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. J. Biol. Chem. 272, 8149-8152 (1997).
13. Sotiropoulos A, Moutoussamy S, Renaudie F et al. Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol. Endocrinol. 10, 998-1009 (1996).
14. + hematopoietic stem cells. Stem Cells 16, 397-403 (1998).
15. Asao H, Okuyama C, Kumaki S et al. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167(1), 1-5 (2001).
16. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway: recent advances and future challenges. Gene 285, 1-24 (2002). • Comprehensive analysis of the Jak-Stat literature.
17. Auguste P, Guillet C, Fourcin M et al. Signaling of type II oncostatin M receptor. J. Biol. Chem. 272(25), 15760-15764 (1997).
18. Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermanns HM. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J. Biol. Chem. 279(34), 36112-36120 (2004).
19. Quentmeier H, Drexler HG, Fleckenstein D et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia 15(8), 1286-1292 (2001).
20. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19(21), 2468-2473 (2000).
21. Matsumura I, Ishikawa J, Nakajima K et al. Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21WAF/CIP1 by Stat5. Mol. Cell. Biol. 17, 2933-2943 (1997).
22. Magne S, Caron S, Charon M, Rouyez M, Dusanter-Fourt I. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol. Cell. Biol. 23, 8934-8945 (2003).
23. Tomita M, Kawakami H, Uchihara JN et al. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 3, 22 (2006).
24. Morcinek JC, Weisser C, Geissinger E, Schartl M, Wellbrock C. Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Oncogene 21(11), 1668-1678 (2002).
25. Debierre-Grockiego F. Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies. Apoptosis 9(6), 717-728 (2004).
26. Dumon S, Santos SC, Debierre-Grockiego F et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18(29), 4191-4199 (1999).
27. Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164(5), 2533-2541 (2000).
28. Moon JJ, Rubio ED, Martino A, Krumm A, Nelson BH. A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J. Biol. Chem. 279(7), 5520-5527 (2004).
29. Prade-Houdellier N, Frebet E, Demur C et al. Human telomerase is regulated by erythropoietin and transforming growth factor-β in human erythroid progenitor cells. Leukemia 21(11), 2304-2310 (2007).
30. Liu X, Robinson GW, Wagner K-U, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179-186 (1997).
31. Teglund S, McKay C, Schuetz E et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93, 841-850 (1998).
32. Feldman GM, Rosenthal LA, Liu X et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90, 1768-1776 (1997).
33. Nakajima H, Liu XW, Wynshaw-Boris A et al. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor α chain induction. Immunity 7, 691-701 (1997).
34. Udy GB, Towers RP, Snell RG et al. Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl Acad. Sci. USA 94, 7239-7244 (1997).
35. Waxman DJ, Ram PA, Park SH, Choi HK. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. J. Biol. Chem. 270(22), 13262-13270 (1995).
36. Moriggl R, Topham DJ, Teglund S et al. Stat5 is required for IL-2 induced cell cycle progression of peripheral T cells. Immunity 10, 249-259 (1999).
37. Imada K, Bloom ET, Nakajima K et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J. Exp. Med. 188, 2067-2074 (1998).
38. Sexl V, Piekorz R, Moriggl R et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but ABL- and BCR/ABL-induced transformation are independent of Stat5. Blood 96(6), 2277-2283 (2000).
39. Yao Z, Cui Y, Watford WT et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl Acad. Sci. USA 104, 1000-1004 (2006). • Informative paper, which has provided tremendous new insights into the requirement of Stat5 in vivo.
40. Hoelbl A, Kovavic B, Kerenyi MA et al. Clarifying the role of Stat5 in lymphoid development and Abelson induced transformation. Blood 107, 4898-4906 (2006).
41. Bromberg JF. Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142 (2002).
42. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101(8), 2940-2954 (2003). • Well-written review on the role of Stats in hematological malignancy.
43. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95(12), 3765-3770 (2000).
44. Aboudola S, Murugesan G, Szpurka H et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am. J. Surg. Pathol. 31(2), 233-239 (2007).
45. Cain JA, Xiang Z, O'Neal J et al. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 109(9), 3906-3914 (2007).
46. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 6(4), 372-375 (1951).
47. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037), 1144-1148 (2005).
48. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005).
49. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 411, 355-365 (2001).
50. Weber-Nordt RM, Egen C, Wehinger J et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88(3), 809-816 (1996). • Definitive study on the specific activation of Stats in primary patient samples.
51. Gouilleux-Gruart V, Gouilleux F, Desaint C et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87(5), 1692-1697 (1996).
52. Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 9(6), 2140-2150 (2003).
53. Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63, 6763-6771 (2003).
54. Baskiewicz-Masiuk M, Machalinski B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur. J. Haematol. 72, 420-429 (2004).
55. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5(3), 172-183 (2005).
56. 1-to-S phase transition in hematopoietic cells. Oncogene 15(19), 2333-2342 (1997).
57. Pendergast AM, Quilliam LA, Cripe LD et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75(1), 175-185 (1993).
58. Skorski T, Bellacosa A, Nieborowska-Skorska M et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16(20), 6151-6161 (1997).
59. Ilaria R, Jr. Van Etten RA. P210 and P190 (Bcr-Abl) induce the tyrosine phsophorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31701-31710 (1996).
60. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of Stat5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene 13, 247-254 (1996).
61. Sonoyama J, Matsumura I, Ezoe S et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J. Biol. Chem. 277(10), 8076-8082 (2002).
62. Huang M, Dorsey JF, Epling-Burnette PK et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21(57), 8804-8816 (2002).
63. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95(6), 2118-2125 (2000).
64. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107(12), 4917-4925 (2006).
65. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 66(13), 6468-6472 (2006).
66. Lacronique V, Boureux A, Valle VD et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278(5341), 1309-1312 (1997).
67. Peeters P, Raynaud SD, Cools J et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase Jak2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90(7), 2535-2540 (1997).
68. Schwaller J, Frantsve J, Aster J et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17(18), 5321-5333 (1998).
69. Ho JM, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93(12), 4354-4364 (1999).
70. Carron C, Cormier F, Janin A et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95(12), 3891-3899 (2000).
71. Sternberg DW, Tomasson MH, Carroll M et al. The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood 98(12), 3390-3397 (2001).
72. Schwaller J, Parganas E, Wang D et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell. 6, 693-704 (2000).
73. Choudhary C, Brandts C, Schwable J et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110(1), 370-374 (2007).
74. Arnould C, Phillipe C, Bourdon V, Gregoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription Stat5b gene is a new partner of retinoic acid receptor α in acute promyelocytic leukemia. Hum. Mol. Genet. 8, 1741-1749 (1999).
75. Dong S, Tweardy DJ. Interactions of Stat5b-RAR α, a novel promyelocytic leukemia fusion protein, with retinoic acid receptor and Stat3 signaling pathways. Blood 99, 2637-2646 (2002).
76. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10(9), 940-954 (1996).
77. Chen CY, Tsay W, Tang JL et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37(3), 300-305 (2003).
78. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br. J. Haematol. 123(4), 654-661 (2003).
79. Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13(11), 1341-1348 (2007).
80. Maurer AB, Wichmann C, Gross A et al. The Stat5-RARα fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 99(8), 2647-2652 (2002).
81. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 100(13), 4272-4290 (2002).
82. Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290(24), 1382 (1974).
83. Griesshammer M, Klippel S, Strunck E et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann. Hematol. 83(6), 364-370 (2004).
84. Campbell PJ, Griesshammer M, Dohner K et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107(5), 2098-2100 (2006).
85. Levine RL, Belisle C, Wadleigh M et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107(10), 4139-4141 (2006).
86. Rudzki Z, Sacha T, Stoj A et al. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. Int. J. Hematol. 86(2), 130-136 (2007).
87. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005).
88. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464), 1054-1061 (2005).
89. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20(10), 3387-3395 (2000).
90. Ward AC. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front. Biosci. 12, 608-618 (2007).
91. Gits J, van Leeuwen D, Carroll HP, Touw IP, Ward AC. Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia 20(12), 2111-2118 (2006).
92. Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 78(11), 3066-3069 (1991).
93. Prchal JT, Crist WM, Goldwasser E, Perrine G, Prchal JF. Autosomal dominant polycythemia. Blood 66(5), 1208-1214 (1985).
94. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin. Hematol. 38(1 Suppl. 2), 10-20 (2001).
95. Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp. Hematol. 27(1), 63-74 (1999).
96. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3(7), e270 (2006).
97. Heath C, Cross NC. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J. Biol. Chem. 279(8), 6666-6673 (2004).
98. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta. Haematol. 107(2), 101-107 (2002).
99. Xiao S, Nalabolu SR, Aster JC et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 18(1), 84-87 (1998).
100. Reiter A, Sohal J, Kulkarni S et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 92(5), 1735-1742 (1998).
101. Smedley D, Demiroglu A, Abdul-Rauf M et al. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5. Neoplasia 1(4), 349-355 (1999).
102. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201-1214 (2003).
103. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 108(10), 3504-3513 (2006).
104. Moriggl R, Sexl V, Kenner L et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell 7, 87-99 (2005). • Important study on the mechanisms underlying pathogenesis mediated via Stat5.
105. Lewis RS, Stephenson SEM, Ward AC. Constitutively-active zebrafish stat5 expands hematopoietic cell populations in vivo. Exp. Hematol. 34, 179-187 (2006).
106. Kato T, Iwama A, Tadokoro Y et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202, 169-179 (2005).
107. Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol. 35(4 Suppl. 1), 105-116 (2007).
108. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 110(8), 2880-2888 (2007). • Key paper providing compelling evidence for the role of Stat5 in leukemia.
109. Joliot V, Cormier F, Medyouf H, Alcalde H, Ghysdael J. Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis. Oncogene 25(33), 4573-4584 (2006).
110. Poincloux R, Cougoule C, Daubon T, Maridonneau-Parini I, Le Cabec V. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells. J. Cell. Physiol. 213(1), 212-220 (2007).
111. Harir N, Pecquet C, Kerenyi M et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood 109(4), 1678-1686 (2007).
112. Lockyer HM, Tran E, Nelson BH. STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J. Immunol. 179(8), 5301-5308 (2007).
113. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1(7), 493-502 (2002).
114. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2(5), 561-566 (1996).
115. Nam S, Williams A, Vultur A et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 6(4), 1400-1405 (2007).
116. + human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol. Pharmacol. 72(3), 788-795 (2007).
117. Yao Q, Nishiuchi R, Kitamura T, Kersey JH. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 19(9), 1605-1612 (2005).
118. Loges S, Tinnefeld H, Metzner A et al. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk. Lymphoma 47(12), 2601-2609 (2006).
119. Growney JD, Clark JJ, Adelsperger J et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106(2), 721-724 (2005).
120. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem. Biophys. Res. Commun. 340(2), 359-368 (2006).
121. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486), 1938-1942 (2000).
122. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001).
123. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344(14), 1038-1042 (2001).
124. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56(1), 100-104 (1996).
125. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001).
126. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475 (2002).
127. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141 (2005).
128. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682), 399-401 (2004).
129. Gumireddy K, Baker SJ, Cosenza SC et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl Acad. Sci. USA 102(6), 1992-1997 (2005).
130. Lucet IS, Fantino E, Styles M et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107(1), 176-183 (2006).
131. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106(3), 996-1002 (2005).
132. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia, (2007).
133. + progenitors via JAK-2/STAT-5 pathway activation. Blood 109(5), 2147-2155 (2007).
134. Scherr M, Chaturvedi A, Battmer K et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107(8), 3279-3287 (2006).
135. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12(10), 1167-1174 (2006).
136. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12(10), 1175-1180 (2006).
137. Klein B, Wijdenes J, Zhang XG et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78(5), 1198-1204 (1991).
138. Tassone P, Neri P, Burger R et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin. Cancer Res. 11(11), 4251-4258 (2005).
139. Burger R, Guenther A, Bakker F et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol. J. 2(1), 42-53 (2001).
140. Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53(4), 851-856 (1993).
141. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 5(12), 1731-1740 (2005).
142. Turkson J, Ryan D, Kim JS et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276(48), 45443-45455 (2001).
143. Ren Z, Cabell LA, Schaefer TS, McMurray JS. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. 13(4), 633-636 (2003).
144. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 16(6), 601-607 (2005). • Useful review highlighting current strategies of targeting Stat3 in cancer therapy.